Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Massachusetts General Hospital
Novartis
Schering-Plough
Information provided by (Responsible Party):
Jennifer Chan, MD, MPH, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00576680
First received: December 17, 2007
Last updated: April 12, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2016
  Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)